Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Daifuku

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 17, 2003
Stealth nucleosides: mode of action and potential use in the treatment of viral diseasesRichard Daifuku
Pharmaceuticals (Basel, Switzerland)|July 21, 2017
5-aza-2',2'-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of CancerRichard Daifuku, Zhenbo Hu, Yogen Saunthararajah
Pharmaceuticals (Basel, Switzerland)|April 26, 2018
NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2',2'-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung CancerRichard Daifuku, Sheila Grimes, Murray Stackhouse
Pharmaceuticals (Basel, Switzerland)|February 9, 2018
Vitamin E Phosphate Nucleoside Prodrugs: A Platform for Intracellular Delivery of Monophosphorylated NucleosidesRichard Daifuku, Michael Koratich, Murray Stackhouse
Annual Review of Microbiology|October 19, 2004
Viral error catastrophe by mutagenic nucleosidesJon P Anderson, Richard Daifuku, Lawrence A Loeb
Antiviral Research|May 14, 2005
KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesisKevin S Harris, William Brabant, Sheila Styrchak, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2008
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patientsJürgen B Bulitta, Ping Zhao, Robert D Arnold, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2008
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patientsJürgen B Bulitta, Ping Zhao, Robert D Arnold, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 17, 2003
Stealth nucleosides: mode of action and potential use in the treatment of viral diseasesRichard Daifuku
Pharmaceuticals (Basel, Switzerland)|July 21, 2017
5-aza-2',2'-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of CancerRichard Daifuku, Zhenbo Hu, Yogen Saunthararajah
Pharmaceuticals (Basel, Switzerland)|April 26, 2018
NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2',2'-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung CancerRichard Daifuku, Sheila Grimes, Murray Stackhouse
Pharmaceuticals (Basel, Switzerland)|February 9, 2018
Vitamin E Phosphate Nucleoside Prodrugs: A Platform for Intracellular Delivery of Monophosphorylated NucleosidesRichard Daifuku, Michael Koratich, Murray Stackhouse
Annual Review of Microbiology|October 19, 2004
Viral error catastrophe by mutagenic nucleosidesJon P Anderson, Richard Daifuku, Lawrence A Loeb
Antiviral Research|May 14, 2005
KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesisKevin S Harris, William Brabant, Sheila Styrchak, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2008
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patientsJürgen B Bulitta, Ping Zhao, Robert D Arnold, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2008
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patientsJürgen B Bulitta, Ping Zhao, Robert D Arnold, et al.
Pageof 1